Overview

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

Status:
Completed
Trial end date:
2009-12-03
Target enrollment:
Participant gender:
Summary
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Panobinostat